Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBT (2016 - 2025)

Altimmune (ALT) has disclosed EBT for 16 consecutive years, with -$19.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 16.77% to -$19.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$84.7 million, a 18.18% increase, with the full-year FY2024 number at -$95.1 million, down 7.53% from a year prior.
  • EBT was -$19.0 million for Q3 2025 at Altimmune, up from -$22.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$5.4 million in Q4 2021 to a low of -$33.5 million in Q3 2021.
  • A 5-year average of -$21.5 million and a median of -$21.7 million in 2022 define the central range for EBT.
  • Biggest YoY gain for EBT was 29.09% in 2022; the steepest drop was 302.44% in 2022.
  • Altimmune's EBT stood at -$5.4 million in 2021, then tumbled by 302.44% to -$21.7 million in 2022, then crashed by 46.17% to -$31.7 million in 2023, then rose by 26.41% to -$23.3 million in 2024, then increased by 18.39% to -$19.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's EBT are -$19.0 million (Q3 2025), -$22.1 million (Q2 2025), and -$20.3 million (Q1 2025).